Newer Drugs for Visceral Leishmaniasis: a Review
نویسندگان
چکیده
Visceral Leishmaniasis (VL) is one of the most neglected tropical diseases worldwide. The diagnosis and treatment of this disease is quite complex. Sodium Antimony Gluconate (SAG) which used to be a very effective treatment has now developed resistance and is potentially a cardio-toxic drug. Pentamidine has now been discarded because of adverse effect of diabetes mellitus. Amphotericin-B is an effective drug but can cause nephrotoxicity. Miltefosine is a new oral effective drug which has recently been introduced in the kala-azar elimination program in the Indian subcontinent. Paromomycin is an injectable aminoglycoside which is quite cheap but can cause ototoxicity and nephrotoxicity. Sitamaquine, an oral antimalarial drug is still in phase-II trial stage. Combination Therapy is been tried with good results. Single dose Ambisome (liposomal Amphotericin-B) though costly is a very good alternative.
منابع مشابه
An Overview of theLaboratory Diagnostic Procedures of Visceral Leishmaniasis (Kala-Azar)
Abstract Visceral leishmaniasis (Kala-azar) is a systemic infection disease that can be diagnosed by some invasive procedures such as splenic, liver biopsy or bone marrow aspiration, whichare determined as the gold standards for diagnosing of this disease. At present, a variety of noninvasive tests having different specificities and sensitivities are available for the diagnosis of visceral ...
متن کاملVisceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches
Visceral leishmaniasis (VL) or kala-azar, a vector-borne protozoan disease, shows endemicity in larger areas of the tropical, subtropical and the Mediterranean countries. WHO report suggested that an annual incidence of VL is nearly 200,000 to 400,000 cases, resulting in 20,000 to 30,000 deaths per year. Treatment with available anti-leishmanial drugs are not cost effective, with varied efficac...
متن کاملVisceral leishmaniasis.
Visceral leishmaniasis (VL) is a vector-borne parasitic disease targeting tissue macrophages. It is among the most neglected infectious diseases. Classical manifestations of VL include chronic fever, hepatosplenomegaly, and pancytopenia. Most cases can be detected through serologic and molecular testing. Although therapy has historically relied on antimonials, newer therapeutic options include ...
متن کاملApplication of Nano Drugs in Treatment of Leishmaniasis
Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most common form of leishmaniasis is cutaneous leishmaniasis (CL) with 1.5 million new cases per year. Correct diagnosis and characterization of the particular parasite is important for evaluating prognosis and prescribing appropriate treatment. The current management of leishmaniasis is drug treatment...
متن کاملVisceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.
Visceral leishmaniasis is common in less developed countries, with an estimated 500000 new cases each year. Because of the diversity of epidemiological situations, no single diagnosis, treatment, or control will be suitable for all. Control measures through case finding, treatment, and vector control are seldom used, even where they could be useful. There is a place for a vaccine, and new imagi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014